Poor
Not Aligned
Patient Risk:
Moderate
Summary
The provided label excerpts only support the CODRIX indication for mild to moderately severe pain. Other claims concern acetaminophen–atorvastatin interactions, Lipitor efficacy, contraindications, and monitoring for liver enzymes, which are not supported or addressed in the supplied prescribing information for CODRIX.
Category Scores
Accurate Statements
CODRIX is indicated for the relief of mild to moderately severe pain.
Supported by Section 1 INDICATIONS AND USAGE: “CODRIX™ is indicated for the relief of mild to moderately severe pain.”
The product combines the analgesic effects of codeine with acetaminophen.
Supported by Section CLINICAL PHARMACOLOGY: “This product combines the analgesic effects of ... codeine ... with ... acetaminophen.”
Unsupported Statements
Acetaminophen in high doses can decrease blood levels of atorvastatin by up to 25%.
The supplied CODRIX label excerpts contain no information about atorvastatin/Lipitor or acetaminophen affecting atorvastatin blood levels.
A decrease in blood levels of atorvastatin may reduce Lipitor effectiveness in lowering cholesterol levels.
The supplied excerpts do not discuss Lipitor efficacy or cholesterol-lowering outcomes related to acetaminophen.
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels and prevent heart disease.
The supplied CODRIX prescribing information excerpts do not provide labeling about Lipitor.
The combination of acetaminophen and Lipitor is not contraindicated.
The supplied CODRIX excerpts do not address acetaminophen + atorvastatin contraindications.
The most significant risk associated with acetaminophen and Lipitor interaction is reduced efficacy of Lipitor, which may lead to decreased cholesterol-lowering effects.
No interaction risk hierarchy or acetaminophen–atorvastatin interaction content is present in the supplied excerpts.
High doses of acetaminophen can cause liver damage.
The provided excerpts do not describe acetaminophen liver damage as a claim.
Liver damage from high-dose acetaminophen may be exacerbated by Lipitor, especially in patients with pre-existing liver disease.
The supplied excerpts do not describe acetaminophen liver toxicity severity, nor any Lipitor-related exacerbation.
Patients should take acetaminophen in the lowest effective dose for the shortest duration necessary to manage pain or fever.
The supplied excerpts do not include this lowest-effective-dose/shortest-duration instruction.
Patients should inform their doctor or pharmacist about taking Lipitor and acetaminophen so they can monitor liver enzyme levels and adjust medications as needed.
The supplied excerpts do not include advice regarding Lipitor co-administration, liver enzyme monitoring, or medication adjustment.
Contradictions
Important Omissions
Any label-based discussion relevant to acetaminophen–atorvastatin (Lipitor) interaction, including contraindications, warnings/precautions, or monitoring instructions for that combination.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several claims assert specific interaction effects (e.g., atorvastatin blood level reduction, liver damage exacerbation) and monitoring instructions that are not supported by the provided CODRIX prescribing information excerpts. This mismatch could misinform clinical decision-making despite the indication claim being supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are about acetaminophen–atorvastatin (Lipitor) pharmacokinetics, efficacy, contraindications, and liver risk/monitoring, none of which are present in the supplied CODRIX label excerpts.
Suggested Improvement
Limit evaluation to information present in the provided label text (e.g., CODRIX indication for mild to moderately severe pain, general cautions, contraindication due to hypersensitivity to codeine/acetaminophen, and warnings about codeine habit formation). Remove or re-verify all Lipitor/atorvastatin-specific interaction and monitoring claims using the relevant FDA label content for those drugs.